Institutions Shift Positions Across Major U.S. Stocks

January 10, 2026 at 19:14 UTC

6 min read

Institutional flows across U.S. banks, pharma, and aerospace stocks after strong Q3 results

Key Points

Large asset managers reported notable third‑quarter moves in banks, insurers, pharma and aerospace names.
Multiple firms, including Truist and General Dynamics, paired solid Q3 beats with new or raised guidance.
Analysts broadly maintained Moderate Buy or Hold stances, but several stocks saw fresh target hikes.
Insider selling was reported at several companies even as institutions increased exposure.

Institutional Investors Rebalance Key Financial Holdings

Recent regulatory filings show active third‑quarter repositioning by major institutional investors across U.S. financial stocks. Parnassus Investments LLC trimmed its stakes in both TransUnion and Truist Financial Corporation by 3.8%. In TransUnion, Parnassus sold 37,743 shares, ending the quarter with 968,311 shares valued at $81.1 million, or about 0.50% of the company. In Truist, it sold 55,390 shares, finishing with 1,421,042 shares worth $65.0 million, representing roughly 0.11% of the bank. Robeco Institutional Asset Management B.V. also reduced its Truist position by 18.3% to 227,593 shares valued at $10.4 million. By contrast, Nisa Investment Advisors LLC cut its Truist holdings by 13.1% to 392,974 shares, while a range of smaller managers initiated or modestly increased positions. In Northern Trust, SG Americas Securities LLC expanded its stake by 228.0% to 75,829 shares worth $10.2 million, underscoring continued institutional interest in large U.S. financial services providers.

Banks and Insurers Post Earnings Beats and Launch Buybacks

Truist Financial reported third‑quarter earnings per share of $1.04, exceeding the $0.99 consensus, on revenue of $5.24 billion, slightly ahead of expectations and up 1.9% year over year. The bank posted a 16.84% net margin and 8.73% return on equity. Its board authorized a $10.0 billion share repurchase program allowing buybacks of up to 15.7% of outstanding stock, and the company paid a quarterly dividend of $0.52 per share, implying a 4.1% yield and a payout ratio of 55.91%. Travelers Companies also delivered a strong quarter, with EPS of $8.14 versus a $6.01 consensus and revenue of $12.47 billion, up 4.8% from a year earlier. The insurer’s net margin reached 12.14% and return on equity 20.28%. Travelers maintained a quarterly dividend of $1.10 per share, a 1.6% yield, while Oregon Public Employees Retirement Fund increased its stake by 31.7% to 25,728 shares. Northern Trust reported EPS of $2.29, slightly above the $2.26 consensus, on $2.03 billion of revenue, up 2.8% year over year, and continues to pay a $0.80 quarterly dividend, a 2.2% yield.

Healthcare Names See Mixed Flows Amid Dividend Increases

In healthcare, Narwhal Capital Management reduced its Merck & Co. position by 6.8% to 136,305 shares valued at $11.4 million, while several other institutions, including Chemung Canal Trust Co. and Diversified Trust Co, increased their Merck holdings. Merck shares recently traded at $110.52, near a 52‑week high of $112.90, and the company reported quarterly EPS of $1.94, below the $2.08 consensus, with a 29.63% net margin and 44.54% return on equity. Merck raised its quarterly dividend from $0.81 to $0.85 per share, a 3.1% yield, and now has a payout ratio of 44.91%. In medical devices, Medtronic PLC attracted divergent institutional moves: Nisa Investment Advisors cut its stake by 46.3% to 222,632 shares, while Oregon Public Employees Retirement Fund raised its holdings by 32.2% to 146,518 shares. Medtronic reported EPS of $1.36 versus a $1.31 consensus on $8.96 billion in revenue, up 6.6% year over year, and maintained a quarterly dividend of $0.71 per share, a 2.9% yield. The company has issued FY 2026 EPS guidance of $5.62 to $5.66.

Aerospace and REITs Attract Capital Despite Insider Selling

Defense and aerospace names also saw significant institutional activity. Narwhal Capital Management reduced its General Dynamics stake by 10.0% to 37,260 shares worth $12.7 million, while Oregon Public Employees Retirement Fund increased its holdings in the company by 32.4% to 28,782 shares valued at $9.8 million. General Dynamics reported quarterly EPS of $3.88, beating the $3.69 consensus, on revenue of $12.91 billion, up 10.6% year over year, and guided FY 2025 EPS to $15.30–$15.35. TransDigm Group drew a 33.6% position increase from Oregon Public Employees Retirement Fund to 6,445 shares worth $8.5 million. TransDigm posted EPS of $10.82 versus a $10.33 consensus on $2.44 billion in revenue, up 11.5% year over year, and issued FY 2026 EPS guidance of $36.49–$38.53. Both companies reported notable insider sales in recent months. In real estate, Ventas was upgraded to a "strong‑buy" by The Goldman Sachs Group and holds a consensus "Moderate Buy" rating with an average price target of $80.65. The healthcare REIT reported EPS of $0.88, slightly above expectations, on $1.49 billion in revenue, up 20.5% year over year, and reaffirmed FY 2025 EPS guidance of $3.45–$3.48. While Robeco Institutional Asset Management cut its Ventas stake by 19.3%, other investors, including SG Americas Securities LLC and several advisory firms, increased positions. Ventas continues to pay a quarterly dividend of $0.48 per share, a 2.6% yield.

Analyst Views Remain Constructive but Selective

Across these names, analyst sentiment is generally constructive but differentiated. TransUnion carries a "Moderate Buy" consensus and a MarketBeat average price target of $103.54, while a separate report cited a $102.07 average target and a Hold rating from one analyst. Truist Financial holds a consensus "Hold" rating with a $52.80 average target, as firms including Citigroup, TD Cowen and Keefe, Bruyette & Woods recently raised price objectives, and Evercore ISI upgraded the stock to "outperform." Merck & Co. is rated on average "Hold" with a $113.25 target, though several firms, including Bank of America and Wolfe Research, have issued Buy or Outperform ratings with higher targets. General Dynamics and TransDigm Group both have "Moderate Buy" consensus ratings, with average targets of $358.50 and $1,596.60, respectively. Medtronic also holds a "Moderate Buy" consensus and a $110.28 average target, supported by multiple recent upgrades. Ventas is similarly rated "Moderate Buy," with analysts citing upside to its current trading range. These ratings, combined with ongoing dividend payments and, in some cases, share repurchase authorizations, frame a landscape in which institutions are selectively adding to or trimming positions while analysts largely maintain positive to neutral outlooks.

Key Takeaways

Third‑quarter 13F filings reveal broad but selective reallocations, with some managers trimming large positions while others add to the same names.
Several companies combined earnings beats with higher or reaffirmed multi‑year EPS guidance, supporting generally positive analyst stances.
Dividend stability and, in Truist’s case, a sizable buyback authorization are central features of the current shareholder return profile across these stocks.